To overcome these limitations, several strategies to prolong IFNα half-life and target the tumor microenvironment have been tested (Fioravanti et al., 2011; Herndon et al., 2012; Jeon et al., 2013; Li et al., 2017; Liang et al., 2018; Yang et al., 2014), including a preclinical gene/cell therapy approach that can deliver constant amounts of IFNα into the liver to significantly curb CRC metastatic growth (Catarinella et al., 2016). This evidence concerns the gene IFNA1 and colorectal carcinoma.